Evidence map›Paper›PMID 34598797›Full record

ReviewTrends in pharmacological sciences2021

Functional intersections between extracellular vesicles and oncolytic therapies.

Ryan A Clark, Zoe G Garman, Richard J Price, Natasha D Sheybani

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Trends in pharmacological sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Ryan A ClarkDepartment of Biomedical Engineering, University of Virginia, Charlottesville, VA, USA; J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL 32611, USA.
Zoe G GarmanDepartment of Biomedical Engineering, University of Virginia, Charlottesville, VA, USA.
Richard J PriceDepartment of Biomedical Engineering, University of Virginia, Charlottesville, VA, USA; Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA, USA.
Natasha D SheybaniDepartment of Biomedical Engineering, University of Virginia, Charlottesville, VA, USA. Electronic address: nds3sa@virginia.edu.
University of Virginia · USUniversity of Florida · US

Funding

Focused Ultrasound Regimens that Synergize with Melanoma ImmunotherapyR01EB030007 · NIBIB · UNIVERSITY OF VIRGINIA · PI BULLOCK, TIMOTHY N, PRICE, RICHARD J. · 2020 to 2023
$2.6M
Targeted Delivery of Brain Penetrating DNA Nanoparticles to Brain TumorsR01CA204968 · NCI · JOHNS HOPKINS UNIVERSITY · PI HANES, JUSTIN S., SUK, JUNG SOO · 2016 to 2020
$2.5M
Genome Editing the Blood-Brain Barrier with Sonoselective Focused UltrasoundR01EB030744 · NIBIB · UNIVERSITY OF VIRGINIA · PI PRICE, RICHARD J. · 2021 to 2024
$2.4M
Focused ultrasound pre-conditioning for augmented nanoparticle penetration in infiltrative gliomasR01EB030409 · NIBIB · UNIVERSITY OF VIRGINIA · PI HANES, JUSTIN S., PRICE, RICHARD J. · 2021 to 2024
$2.3M
ImmunoPET Assessment of anti-CD47 Immunotherapy Delivery to Glioblastoma with Focused UltrasoundR21NS118278 · NINDS · UNIVERSITY OF VIRGINIA · PI PRICE, RICHARD J. · 2020 to 2020
$420k
Ceramide Nanoliposomes in Combination with Focused Ultrasound for Treating Breast CancerR21CA230088 · NCI · UNIVERSITY OF VIRGINIA · PI KESTER, MARK, PRICE, RICHARD J. · 2018 to 2019
$355k
Focused Ultrasound and Multifunctional Nanoparticle Vaccines as Adjuvant Strategies for Cancer ImmunotherapyK00CA234954 · NCI · STANFORD UNIVERSITY · PI SHEYBANI, NATASHA DIBA · 2020 to 2021
$183k
NCI NIH HHS K00 CA234954NCI NIH HHS R01 CA204968NCI NIH HHS R21 CA230088NIBIB NIH HHS R01 EB030007NIBIB NIH HHS R01 EB030409NIBIB NIH HHS R01 EB030744NINDS NIH HHS R21 NS118278
6 · The paper itself

Abstract

Minimally invasive focal therapies for nonviral oncolysis are a cornerstone of cancer therapeutics. Our ability to optimally deploy oncolytic therapies and identify synergistic combination approaches requires a deeper understanding of elicited biological responses. Extracellular vesicles (EV), which orchestrate a variety of pathophysiological processes and have a critical role in the evolution of primary and disseminated tumors, are now known to be potently modulated by oncolytic focal therapies, such as radiotherapy, photodynamic therapy (PDT), and therapeutic ultrasound (TUS). In this review, we summarize the diverse impacts of the aforementioned therapeutic modalities on EV biology, and highlight the most recent advances in EV-based drug delivery systems leveraging these modalities.

Indexed as

Extracellular VesiclesNeoplasmsDrug Delivery SystemsHumanscancerexosomesextracellular vesiclesfocal therapyoncolytic therapytherapeutic ultrasound

Identifiers

PMID34598797
PMCPMC8526420
OpenAlexW3204707855

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.